Jennison Associates’s Adverum Biotechnologies ADVM Stock Holding History

Jennison Associates’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-30,208	Closed	-$1.06M	–	652
2017 Q4	$1.06M	Buy	+30,208	New	+$994K	﹤0.01%	576
2015 Q2	–	Sell	-7,848	Closed	-$3.18M	–	730
2015 Q1	$3.18M	Buy	7,848 +25	+0.3%	+$10.6K	﹤0.01%	556
2014 Q4	$4.22M	Sell	7,823 -2,177	-22%	-$839K	﹤0.01%	518
2014 Q3	$3.42M	Buy	+10,000	New	+$2.98M	﹤0.01%	537

Other funds holding ADVM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Jennison Associates's ADVM Position: Q1 2018 in Review

Jennison Associates sold out of Adverum Biotechnologies (ADVM) in Q1 2018, closing a stake of 30,208 shares — an estimated $1.06M sold.

Jennison Associates first reported a position in ADVM in Q3 2014 and held it in 4 quarters. The position peaked at $4.22M in Q4 2014. 96 funds tracked by Wall St. Rank hold ADVM as of Q1 2018.

Jennison Associates reported no remaining Adverum Biotechnologies position as of Q1 2018 after selling out during the quarter.
Jennison Associates sold 30,208 Adverum Biotechnologies shares in Q1 2018, an estimated $1.06M.
Jennison Associates first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 4 quarters.
Jennison Associates's Adverum Biotechnologies position peaked at $4.22M in Q4 2014.
96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2018.

Based on Jennison Associates's 13F filing for Q1 2018, filed 20 Apr 2018.